Abstract:Hyperkalemia in hemodialysis patients is associated with high mortality, but prescription of low dialysate potassium concentrations to decrease serum potassium levels is associated with a high incidence of sudden cardiac arrest or sudden death. Improved clinical outcomes for these patients may be possible if rapid and substantial intradialysis decreases in serum potassium concentration can be avoided while maintaining adequate potassium removal. Data from kinetic modeling sessions during the HEMO Study of the … Show more
“…7,8 Potassium has the potential to move freely across the dialyzer membrane during the HD session, typically being transferred from a patient’s blood into the dialysate. 9 The dialysate potassium (DK) concentration is a modifiable factor that can alter SK concentrations throughout the HD session and thus potentially impacts the risk for arrhythmias and cardiac arrest. 10 Results of studies examining DK effects on sudden death and all-cause mortality have been mixed.…”
Background
Sudden death is a leading cause of death in patients on maintenance hemodialysis (HD). During HD sessions, the gradient between serum and dialysate levels results in rapid electrolytes shifts, which may contribute to arrhythmias and sudden death. Controversies exist on the optimal electrolyte concentration in the dialysate; specifically, it is unclear whether patient outcomes differ among those treated with dialysate potassium (DK) concentration of 3 mEq/L compared to 2 mEq/L.
Study Design
Prospective cohort study
Setting & Participants
55,183 patients from 20 countries in the Dialysis Outcomes and Practice Patterns Study phases 1–5 (1996–2015).
Predictor
DK at study entry.
Outcomes
Cox regression was used to estimate the association between DK and both all-cause mortality and an arrhythmia composite outcome (arrhythmia-related hospitalization or sudden death), adjusting for potential confounders.
Results
During a median follow-up of 16.5 months, 24% of patients died and 7% had an arrhythmia composite outcome. No meaningful difference in clinical outcomes were observed for patients treated with DK 3 vs. 2 mEq/L; the adjusted hazard ratio (95% CI) was 0.96 (0.91, 1.01) for mortality and 0.98 (0.88, 1.08) for the arrhythmia composite. Results were similar across pre-dialysis serum potassium (SK) levels. As in prior studies, higher SK was associated with adverse outcomes. However, DK only had minimal impact on SK measured pre-dialysis (+0.09 mEq/L SK per 1 mEq/L DK; 95% CI: 0.05, 0.14).
Limitations
Data were not available on delivered (vs. prescribed) DK and post-dialysis SK; possible unmeasured confounding.
Conclusions
In combination, these results suggest that approaches other than altering DK concentration (e.g., education on dietary K sources, prescription of K-binding medications) may merit further attention to reduce risks associated with high SK.
“…7,8 Potassium has the potential to move freely across the dialyzer membrane during the HD session, typically being transferred from a patient’s blood into the dialysate. 9 The dialysate potassium (DK) concentration is a modifiable factor that can alter SK concentrations throughout the HD session and thus potentially impacts the risk for arrhythmias and cardiac arrest. 10 Results of studies examining DK effects on sudden death and all-cause mortality have been mixed.…”
Background
Sudden death is a leading cause of death in patients on maintenance hemodialysis (HD). During HD sessions, the gradient between serum and dialysate levels results in rapid electrolytes shifts, which may contribute to arrhythmias and sudden death. Controversies exist on the optimal electrolyte concentration in the dialysate; specifically, it is unclear whether patient outcomes differ among those treated with dialysate potassium (DK) concentration of 3 mEq/L compared to 2 mEq/L.
Study Design
Prospective cohort study
Setting & Participants
55,183 patients from 20 countries in the Dialysis Outcomes and Practice Patterns Study phases 1–5 (1996–2015).
Predictor
DK at study entry.
Outcomes
Cox regression was used to estimate the association between DK and both all-cause mortality and an arrhythmia composite outcome (arrhythmia-related hospitalization or sudden death), adjusting for potential confounders.
Results
During a median follow-up of 16.5 months, 24% of patients died and 7% had an arrhythmia composite outcome. No meaningful difference in clinical outcomes were observed for patients treated with DK 3 vs. 2 mEq/L; the adjusted hazard ratio (95% CI) was 0.96 (0.91, 1.01) for mortality and 0.98 (0.88, 1.08) for the arrhythmia composite. Results were similar across pre-dialysis serum potassium (SK) levels. As in prior studies, higher SK was associated with adverse outcomes. However, DK only had minimal impact on SK measured pre-dialysis (+0.09 mEq/L SK per 1 mEq/L DK; 95% CI: 0.05, 0.14).
Limitations
Data were not available on delivered (vs. prescribed) DK and post-dialysis SK; possible unmeasured confounding.
Conclusions
In combination, these results suggest that approaches other than altering DK concentration (e.g., education on dietary K sources, prescription of K-binding medications) may merit further attention to reduce risks associated with high SK.
“…Potassium kinetic parameters based on a pseudo one‐compartment model were previously determined from thrice weekly hemodialysis kinetic modeling sessions during the HEMO Study and were used in this study to represent a typical hemodialysis patient population. The HEMO Study was approved by the institutional review board at each of the 15 clinical centers, and all patients gave written informed consent .…”
Section: Methodsmentioning
confidence: 99%
“…Potassium kinetic parameters based on a pseudo one‐compartment model were previously determined from thrice weekly hemodialysis kinetic modeling sessions during the HEMO Study and were used in this study to represent a typical hemodialysis patient population. The HEMO Study was approved by the institutional review board at each of the 15 clinical centers, and all patients gave written informed consent . Kinetic modeling sessions were performed by collection of blood samples predialysis, 60 minutes after starting the treatment, 20 seconds after stopping the treatment using a slow flow technique, and 30 minutes after the end of the treatment.…”
Section: Methodsmentioning
confidence: 99%
“…We have recently used a pseudo one‐compartment mathematical model to describe potassium kinetics during thrice weekly hemodialysis based on data from a large number of patients in the HEMO Study . That study demonstrated significant interpatient variability in potassium kinetics that could be characterized by individualized potassium kinetic parameters.…”
The prescription of dialysate potassium concentration during short daily and long nocturnal (high dose) hemodialysis (HD) is challenging due to limited clinical experience with such modalities. The aim here is to propose a quantitative approach for prescribing dialysate potassium concentrations during high-dose HD. Potassium kinetic parameters based on a pseudo one-compartment model from 547 patients participating in the HEMO Study were used for prediction purposes in this study. Patients were categorized based on the prescribed dialysate potassium concentration during thrice weekly HD as 1K (mean of 1.02 mEq/L, N = 60), 2K (2.01 mEq/L, N = 437), or 3K (3.01 mEq/L, N = 50). Dialysate potassium concentrations were then predicted for each patient during short daily and long nocturnal HD based on a pseudo one-compartment model to maintain the identical weekly dialytic potassium removal and predialysis serum potassium concentration as during thrice weekly HD. Predicted prescribed dialysate potassium concentrations for short daily HD were 0.18-0.45 mEq/L higher than during thrice weekly HD but were approximately 4 (3.72-4.26) mEq/L for all patients during long nocturnal HD. The intradialytic decrease in serum potassium concentration was predicted to be reduced by more than one-half during short daily HD and by approximately three-quarters during long nocturnal HD of that during thrice weekly HD. Prescribed dialysate potassium concentration during high-dose HD modalities can be quantitatively predicted using a pseudo one-compartment kinetic model. High-dose HD modalities may improve clinical outcomes by reducing intradialytic decreases in serum potassium.
“…calcium, potassium and phosphorus, that play a crucial role for hydro-electrolyte equilibria. [16][17][18] To achieve more effective prediction models, multi-pool models have been introduced, allowing to describe the simultaneous contribution of different plasma solutes. 19 However, none of these models aim at characterizing the patientspecific solute kinetics in HD, apart from Ursino et al, 19 in which an individual estimation of few parameters characterizing solute kinetics has been performed.…”
Hemodialysis is the most common therapy to treat renal insufficiency. However, notwithstanding the recent improvements, hemodialysis is still associated with a non-negligible rate of comorbidities, which could be reduced by customizing the treatment. Many differential compartment models have been developed to describe the mass balance of blood electrolytes and catabolites during hemodialysis, with the goal of improving and controlling hemodialysis sessions. However, these models often refer to an average uremic patient, while on the contrary the clinical need for customization requires patient-specific models. In this work, we assume that the customization can be obtained by means of patient-specific model parameters. We propose and validate a Bayesian approach to estimate the patientspecific parameters of a multi-compartment model, and to predict the single patient's response to the treatment, in order to prevent intra-dialysis complications. The likelihood function is obtained by means of a discretized version of the multi-compartment model, where the discretization is in terms of a Runge-Kutta method to guarantee convergence, and the posterior densities of model parameters are obtained through Markov Chain Monte Carlo simulation. Results show fair estimations and the applicability in the clinical practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.